Cell or stem cell-derived products such as stem cell-based regenerative treatments and CAR-T cell therapies have seen increasing use in treatment of blood cancers such as leukemias and lymphomas; the Centre’s move is aimed at strengthening regulatory oversight of such advanced and emerging medical technologies